Ocular Therapeutix’s (OCUL) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) in a report published on Wednesday morning. The brokerage currently has a $10.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts also recently commented on the stock. ValuEngine downgraded shares of Ocular Therapeutix from a hold rating to a sell rating in a report on Friday, August 4th. BTIG Research restated a neutral rating on shares of Ocular Therapeutix in a research note on Monday, July 17th. Morgan Stanley restated an equal weight rating and issued a $8.00 target price (down from $16.00) on shares of Ocular Therapeutix in a research note on Friday, July 14th. Cantor Fitzgerald dropped their target price on shares of Ocular Therapeutix from $35.00 to $21.00 and set an overweight rating on the stock in a research note on Wednesday, July 12th. Finally, Zacks Investment Research downgraded shares of Ocular Therapeutix from a buy rating to a hold rating in a research note on Tuesday, May 23rd. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of Hold and an average price target of $22.14.

Ocular Therapeutix (OCUL) traded up 2.94% during trading on Wednesday, hitting $5.95. 337,824 shares of the stock were exchanged. The stock’s 50 day moving average is $7.24 and its 200-day moving average is $8.63. The company’s market cap is $172.88 million. Ocular Therapeutix has a one year low of $4.82 and a one year high of $11.91.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.05. The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.51 million. Ocular Therapeutix had a negative net margin of 3,005.52% and a negative return on equity of 101.03%. The business’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.46) earnings per share. On average, equities research analysts expect that Ocular Therapeutix will post ($2.21) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Ocular Therapeutix’s (OCUL) “Buy” Rating Reiterated at HC Wainwright” was published by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.thestockobserver.com/2017/08/12/ocular-therapeutixs-ocul-buy-rating-reiterated-at-hc-wainwright.html.

A number of institutional investors have recently modified their holdings of OCUL. SG Americas Securities LLC bought a new position in shares of Ocular Therapeutix during the first quarter worth approximately $455,000. JPMorgan Chase & Co. bought a new position in shares of Ocular Therapeutix during the first quarter worth approximately $3,394,000. GWM Advisors LLC bought a new position in shares of Ocular Therapeutix during the first quarter worth approximately $381,000. NEXT Financial Group Inc bought a new position in shares of Ocular Therapeutix during the first quarter worth approximately $480,000. Finally, Parametric Portfolio Associates LLC increased its position in shares of Ocular Therapeutix by 1.3% in the first quarter. Parametric Portfolio Associates LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $284,000 after buying an additional 401 shares in the last quarter. Institutional investors and hedge funds own 65.04% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

Analyst Recommendations for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply